Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

RNAZ

TransCode Therapeutics Inc

Last Close
May 17 • 04:00PM ET
1.15
Dollar change
+0.27
Percentage change
29.97 		%
Scroll to Statements
Index- P/E- EPS (ttm)-205.92 Insider Own0.53% Shs Outstand6.57M Perf Week-18.44%
Market Cap7.56M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float6.54M Perf Month129.08%
Income-17.06M PEG- EPS next Q-0.65 Inst Own5.51% Short Float2.29% Perf Quarter69.37%
Sales0.00M P/S- EPS this Y98.09% Inst Trans-2.12% Short Ratio0.14 Perf Half Y-90.00%
Book/sh0.79 P/B1.46 EPS next Y66.16% ROA-264.82% Short Interest0.15M Perf Year-99.53%
Cash/sh0.75 P/C1.54 EPS next 5Y- ROE-784.63% 52W Range0.42 - 309.60 Perf YTD-82.55%
Dividend Est.- P/FCF- EPS past 5Y-28.81% ROI-372.05% 52W High-99.63% Beta-0.05
Dividend TTM- Quick Ratio2.48 Sales past 5Y0.00% Gross Margin- 52W Low173.81% ATR (14)0.25
Dividend Ex-Date- Current Ratio2.48 EPS Y/Y TTM81.88% Oper. Margin0.00% RSI (14)59.69 Volatility61.01% 31.55%
Employees10 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q99.76% Payout- Rel Volume3.62 Prev Close0.88
Sales Surprise- EPS Surprise-125.93% Sales Q/Q- EarningsApr 01 BMO Avg Volume1.08M Price1.15
SMA2052.91% SMA5066.96% SMA200-92.65% Trades Volume3,899,025 Change29.97%
May-13-24 10:20AM
Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private
(InvestorPlace) -56.30%
08:48AM
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
(InvestorPlace)
08:30AM
TransCode Therapeutics Open Letter to Shareholders
(GlobeNewswire)
07:23AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
(InvestorPlace)
Apr-15-24 09:00AM
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
(GlobeNewswire) -13.68%
09:10AM Loading…
Apr-03-24 09:10AM
TransCode Therapeutics Reports 2023 Results; Provides Business Update
(GlobeNewswire)
Mar-28-24 08:30AM
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
(GlobeNewswire)
Mar-11-24 09:00AM
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
(GlobeNewswire) -8.60%
Mar-06-24 04:15PM
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
(GlobeNewswire)
Feb-20-24 08:00AM
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic
(GlobeNewswire)
Jan-31-24 04:05PM
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market
(GlobeNewswire) -7.25%
Jan-29-24 08:30AM
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
(GlobeNewswire)
Jan-22-24 04:45PM
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
(GlobeNewswire)
Jan-19-24 01:09PM
TransCode (RNAZ) Down 50% on Issue of New Common Stock
(Zacks) -25.22%
Jan-18-24 01:27PM
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
(GlobeNewswire) -49.54%
04:05PM Loading…
Jan-12-24 04:05PM
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
(GlobeNewswire) -8.09%
Jan-11-24 08:00AM
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
(GlobeNewswire) +10.57%
Jan-04-24 08:05AM
TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives
(GlobeNewswire) -8.18%
Dec-12-23 08:30AM
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
(GlobeNewswire) -9.38%
Dec-05-23 09:00AM
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
(GlobeNewswire)
Dec-04-23 04:10PM
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
(GlobeNewswire)
Nov-30-23 02:53PM
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
(GlobeNewswire)
Nov-14-23 04:30PM
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
(GlobeNewswire)
Oct-30-23 04:33PM
TransCode Therapeutics Withdraws Public Offering
(GlobeNewswire) +10.36%
Oct-27-23 08:16AM
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
(InvestorPlace) -21.61%
08:00AM
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
(GlobeNewswire)
Oct-26-23 04:19PM
TransCode Therapeutics Announces Public Offering of Common Stock
(GlobeNewswire) +12.13%
08:00AM
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
(GlobeNewswire)
Oct-24-23 08:00AM
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
(GlobeNewswire) +40.39%
Oct-16-23 08:00AM
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
(GlobeNewswire) +5.84%
04:02PM Loading…
Sep-28-23 04:02PM
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
(GlobeNewswire)
Sep-25-23 08:01PM
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
(GlobeNewswire) +284.04%
08:30AM
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
(GlobeNewswire)
Aug-23-23 08:00AM
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
(GlobeNewswire)
Aug-14-23 04:45PM
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
(GlobeNewswire)
Jul-31-23 07:00AM
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
(GlobeNewswire) -5.17%
Jul-13-23 12:43PM
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi
(Newsfile) -6.71%
Jul-10-23 09:55AM
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
(Zacks)
Jul-05-23 07:00AM
TransCode Therapeutics CEO Letter to Shareholders
(GlobeNewswire)
Jun-28-23 03:49PM
TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate
(News Direct)
Jun-23-23 09:24AM
Daily Vickers Top Buyers & Sellers for 06/23/2023
(Argus Research)
Jun-22-23 07:00AM
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
(GlobeNewswire) -7.75%
Jun-09-23 04:05PM
TransCode Therapeutics Announces Closing of $7 Million Public Offering
(GlobeNewswire)
Jun-07-23 11:00AM
Why TransCode Therapeutics Stock Is Trading Higher Premarket Today
(Benzinga)
Jun-06-23 05:29PM
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
(GlobeNewswire) -19.75%
04:01PM
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
(GlobeNewswire)
May-22-23 07:00AM
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
(GlobeNewswire) -5.38%
Apr-27-23 07:00AM
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
(GlobeNewswire) -9.65%
Apr-26-23 08:00AM
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
(GlobeNewswire)
Apr-14-23 07:00AM
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
(GlobeNewswire)
Apr-06-23 07:00AM
TransCode Therapeutics to present at AACR Annual Meeting 2023
(GlobeNewswire) -14.90%
Apr-05-23 07:00AM
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
(GlobeNewswire) +31.52%
Apr-04-23 09:00PM
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
(GlobeNewswire) -5.54%
Apr-03-23 08:00AM
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
(GlobeNewswire)
Mar-31-23 04:01PM
TransCode Therapeutics Reports 2022 Results; Provides Business Update
(GlobeNewswire)
Feb-28-23 07:00AM
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
(GlobeNewswire) +9.04%
Feb-22-23 08:00AM
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
(GlobeNewswire)
Feb-18-23 08:42AM
Great news for TransCode Therapeutics, Inc. (NASDAQ:RNAZ): Insiders acquired stock in large numbers last year
(Simply Wall St.)
Feb-17-23 04:10PM
TransCode Therapeutics Announces Closing of $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
(GlobeNewswire)
Feb-16-23 08:00AM
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
(GlobeNewswire) -24.73%
Feb-01-23 07:49AM
Why TransCode Therapeutics (RNAZ) Shares Are Trading Higher Today
(Benzinga) +16.01%
Jan-31-23 04:05PM
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
(GlobeNewswire) -17.49%
Dec-29-22 09:34AM
FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor Patients
(Benzinga) -6.54%
08:00AM
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
(GlobeNewswire)
Dec-07-22 02:37PM
Small Biotechs Are Pulling Public Offerings, IPOs Amid 'Current Market Conditions'
(Benzinga) +133.44%
Dec-06-22 04:20PM
TransCode Therapeutics Announces Withdrawal of Registration Statement
(GlobeNewswire)
Nov-30-22 07:00AM
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
(GlobeNewswire) -6.76%
Nov-14-22 04:15PM
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
(GlobeNewswire)
Nov-09-22 07:00AM
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
(GlobeNewswire) -14.24%
Nov-08-22 03:40PM
Sidoti's November Micro-Cap Virtual Conference
(ACCESSWIRE)
Nov-07-22 08:00AM
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
(GlobeNewswire)
Oct-26-22 10:51AM
TransCode Therapeutics Shares Shoot Higher After Encouraging Preclinical Data From Lead Cancer Candidate
(Benzinga) +6.48%
07:00AM
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
(GlobeNewswire)
Oct-19-22 08:00AM
TransCode Therapeutics: Invitation to The ThinkEquity Conference
(Newsfile) -5.69%
Oct-13-22 07:00AM
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
(GlobeNewswire)
Sep-27-22 08:00AM
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
(GlobeNewswire)
Sep-08-22 08:00AM
TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
(GlobeNewswire) +7.69%
Aug-15-22 04:15PM
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
(GlobeNewswire)
Aug-02-22 07:00AM
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
(GlobeNewswire)
Jul-11-22 04:05PM
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
(GlobeNewswire)
Jul-04-22 03:13PM
A number of insiders bought TransCode Therapeutics, Inc. (NASDAQ:RNAZ) stock last year, which is great news for shareholders
(Simply Wall St.)
Jun-09-22 09:00AM
TransCode Therapeutics to Participate at BIO International Convention
(GlobeNewswire)
Jun-01-22 09:00AM
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
(GlobeNewswire)
May-20-22 09:00AM
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
(GlobeNewswire)
May-19-22 09:00AM
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
(GlobeNewswire)
May-16-22 08:30AM
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
(GlobeNewswire) -8.00%
Apr-13-22 09:00AM
TransCode Therapeutics CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
(GlobeNewswire)
Apr-05-22 07:17AM
Dolby's (DLB) Transcode API to Speed Up Workflow Creation
(Zacks)
Mar-31-22 04:30PM
TransCode Therapeutics Reports 2021 Results; Provides Business Update
(GlobeNewswire) +5.49%
Mar-25-22 12:00PM
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
(GlobeNewswire) -5.38%
Mar-23-22 09:00AM
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders
(GlobeNewswire)
Feb-14-22 09:00AM
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
(GlobeNewswire)
Feb-10-22 09:46AM
CORRECTION --TransCode Therapeutics
(GlobeNewswire)
08:30AM
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
(GlobeNewswire)
Jan-06-22 03:17PM
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
(GlobeNewswire)
Dec-06-21 07:10PM
TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference
(GlobeNewswire)
Nov-18-21 10:57AM
Companies Like TransCode Therapeutics (NASDAQ:RNAZ) Are In A Position To Invest In Growth
(Simply Wall St.) -6.25%
Nov-15-21 04:01PM
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
(Business Wire)
Nov-09-21 07:30AM
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit
(Newsfile) -7.95%
Sep-30-21 04:01PM
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
(Business Wire) -5.08%
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dudley Robert MichaelChief Executive OfficerSep 28 '23Buy0.5198,00049,980180,262Oct 02 04:37 PM
Fitzgerald Thomas AChief Financial OfficerSep 28 '23Buy0.5149,35025,16856,318Oct 02 04:39 PM
Dudley Robert MichaelChief Executive OfficerJun 21 '23Buy2.6512,00031,81882,262Jun 22 06:23 PM
Dudley Robert MichaelChief Executive OfficerJun 20 '23Buy2.556,60716,84770,262Jun 22 06:23 PM
Dudley Robert MichaelChief Executive OfficerJun 09 '23Buy2.7619,00052,440912,114Jun 13 04:16 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.